Grifols Donates 140 Million IU of Blood Clotting Factors to the WFH Humanitarian Aid Program

Grifols will donate a minimum of 140 million international units (IU) of blood clotting factor medicines (Factor VIII) to the World Federation of Hemophilia (WFH) Humanitarian Aid Program over the next five years.

This announcement is a continuation of the Company’s three-year commitment from 2014, bringing the total humanitarian aid commitment to more than 200M IU of Factor VIII over eight years.  Grifols’ direct contribution to the WFH Humanitarian Aid Program builds on the Company’s participation in Project Recovery, which transforms previously unused cryoprecipitate from Canadian blood donors into medicines that treat hemophilia patients in developing countries.

Grifols produces plasma-derived medicines to treat rare, chronic diseases such as hemophilia and also develops solutions for the diagnoses of bleeding disorders. The company plans to increase its production of blood clotting factor medicines to specifically meet its donation commitment to the WFH.

Grifols President, Victor Grifols Roura said that World Hemophilia Day represents ideal timing for Grifols to reaffirm our long-standing commitment to bleeding disorders and the hemophilia community. Their philosophy aligns fully with the mission of WFH, sharing a clear passion for providing adequate treatment for all patients regardless of where they live.

WFH CEO and Executive Director of WFH USA, Alain Bauman said that Since its creation in 1996 the WFH humanitarian Aid Program has benefitted more than 100,000 people in 90 countries. They are grateful for their contributors’ commitment and support for their mission, such as Grifols, to improve the diagnosis and access to care for people with bleeding disorders who wouldn’t otherwise receive the treatment they need. They have seen time and time again the dramatic positive impact on quality of life that such donations make on patients.